INSIGHTS ON CONTRACT PHARMA MANUFACTURING

• Benefits Of 5KL Bioreactor When Outsourcing Late-Phase Biologics Drug Substance Manufacturing

  Watch this webinar today to discover how Thermo Fisher Scientific is addressing and overcoming two critical, current challenges in upstream bioprocessing.

• Biologics Drug Product: Formulation, Tech Transfer, Delivery Strategies

  This webinar covers the key considerations for formulation screening of therapeutic proteins with a focus on maintaining protein stability and avoiding aggregation.

• The Art and Science Of Tech Transfer – Transferring Vaccine Production

  As COVID 19 vaccine development and manufacturing has rightfully become a global priority, it has left other vaccine producers and public health organizations searching for manufacturing capacity. Facilities committed to COVID 19 production are forcing non-COVID 19 vaccine makers to shift their production needs to other facilities, requiring a technology transfer in each case. 

• Saving Development Time With A Single Vendor Approach

  This webinar provides an overview of Thermo Fisher Scientific’s Quick to Care^TM program. Watch it to learn how a single-vendor with a cohesive global network can help you accelerate the drug development process and reach the market sooner.

• Vaccine Capacity Musical Chairs

  In the past six months, I’ve spoken to more vaccine developers than I have in the previous eight years, all of them searching for production capacity. With the good news from Pfizer, Moderna, and many other organizations completing their clinical trials and vaccine production, and distribution being maybe only weeks away, does this mean the music has stopped and it is time to grab a chair?

• Art And Science Of Tech Transfer — Establishing The Path For Success

  Pharmaceutical technology transfer often invokes images of a complicated set of activities required to transfer the development and manufacturing of a product, or products, from one facility to another. This article shares five features of a successful tech transfer, imperatives that we have learned with a focus on drug sponsors working with CDMOs. These imperatives, when applied to project management operations, can deliver extraordinary results.

• Residual Host Cell DNA Quantitation: In-House Vs. Commercial

  Here, we illustrate approaches for analytical method development and the challenges that may be encountered, particularly in the development of a quantitative assay for residual host cell DNA.  

• Quantification Of Vector Genomic, Residual DNA In Gene Therapy Vectors

  Bringing cell and gene therapy drugs to market requires improvement in many areas, including analytical testing methods, which are used to determine the safety, strength, and purity of viral vectors.

• Sterile Parenteral, Aseptic Fill-Finish, Helping You Take Your Drug from Concept To Clinical To Commercial

  Pii can provide you with the state-of-the-art GENiSYS R aseptic filling and closure system. The GENiSYS R aseptic filling and closure system is a fully robotic, automated line providing accurate precision-filling and eliminating the loss of costly drug product.